EUVIMEDEUVIMED entdecken
Multizentrische Studie

Effect of Intratumoral PD-L1 Expression on Treatment Efficacy of ALK Tyrosine Kinase Inhibitors for Advanced or Recurrent ALK-Positive Non-small Cell Lung Cancer

Ryo Sawada, Tadaaki Yamada, Yasuhiro Goto, Yoshiki Negi, Akira Nakao, Akihiro Yoshimura, Naoki Furuya, Tomohiro Oba, Makoto Hibino, Haruka Nakatani, Hirokazu Taniguchi, Aya Ohtsubo und 5 weitere

Medical Oncology · 2026

DOI: 10.1007/s12032-026-03477-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Medical Oncology, 2026. Verfasst von Ryo Sawada und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto, 60…. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, B7-H1 Antigen, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to clarify the association between programmed death-ligand 1 (PD-L1) expression and the treatment efficacy of anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs), particularly alectinib, in patients with advanced or recurrent ALK -positive non-small cell lung cancer (NSCLC). This multicenter retrospective cohort study involved 129 patients with advanced or recurrent ALK -positive NSCLC treated between July 2014 and December 2022 at 13 Japanese institutions. All patients had available PD-L1 tumor proportion score (TPS) data evaluated using the 22C3 antibody and received at least one ALK-TKI. The primary endpoint was progression-free survival (PFS) with the first ALK-TKI. The secondary endpoints were overall survival (OS), objective response rate (ORR), and incidence of grade ≥ 3 adverse events (AEs). The low- (< 50%, n = 74) and high-PD-L1 groups (≥ 50%, n = 55) showed comparable ORRs (86.5%, 95% confidence interval [CI]: 76.5%–93.3% vs. 85.5%, 95% CI: 73.3%–93.5%; p = 1.00), median PFS (29.7, 95% CI: 18.8–51.2 months vs. 35.0, 95% CI: 16.6–54.2 months; hazard ratio [HR]: 1.01, 95% CI: 0.63–1.63; p = 0.961), and median OS (119.9, 95% CI: 60.1 months to NA vs. 76.6, 95% CI: 43.0 months to NA; HR: 1.74, 95% CI: 0.91–3.32; p = 0.095). PD-L1 expression was not significantly associated with survival. However, severe (grade ≥ 3) AEs were more common in the high-PD-L1 group than in the low-PD-L1 group (21.8% vs. 5.4%). No patients received concomitant cytotoxic chemotherapy or immune checkpoint inhibitors during treatment with the first ALK-TKI, and the frequency of prior systemic therapy before the first ALK-TKI was similar between the two PD-L1 groups. Intratumoral PD-L1 expression was not significantly associated with the efficacy of ALK-TKI therapy in this cohort of patients with ALK -positive NSCLC, particularly those treated with alectinib. The numerical OS difference and imbalance in grade ≥ 3 AEs should be interpreted cautiously because of the retrospective design and limited number of OS events. Further prospective studies with larger cohorts are warranted to validate these observations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anaplastic Lymphoma KinaseB7-H1 AntigenCarcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCarbazolesNeoplasm Recurrence, LocalRetrospective StudiesTreatment OutcomeCohort StudiesPiperidines

Stichwörter der Autor:innen

ALK rearrangementALK tyrosine kinase inhibitorPD-L1alectinibnon-small cell lung cancerprognostic biomarkerprogression-free survival

Substanzen

alectinibALK protein, humanAnaplastic Lymphoma KinaseB7-H1 AntigenCarbazolesCD274 protein, humanProtein Kinase InhibitorsPiperidines

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. tayamada@koto.kpu-m.ac.jp.
  • Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, 470-1192, Aichi, Japan.
  • Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, 663-8501, Hyogo, Japan.
  • Department of Respiratory Medicine, Fukuoka University School of Medicine, Fukuoka, 814-0133, Japan.
  • Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, 602- 8026, Japan.

Zitieren

APA

Sawada, R., Yamada, T., Goto, Y., Negi, Y., Nakao, A., Yoshimura, A., Furuya, N., Oba, T., Hibino, M., Nakatani, H., Taniguchi, H., Ohtsubo, A., Watanabe, S., Yamada, T., Chihara, Y., Kijima, T., & Takayama, K. (2026). Effect of Intratumoral PD-L1 Expression on Treatment Efficacy of ALK Tyrosine Kinase Inhibitors for Advanced or Recurrent ALK-Positive Non-small Cell Lung Cancer. Medical Oncology. https://doi.org/10.1007/s12032-026-03477-2

Vancouver

Sawada R, Yamada T, Goto Y, Negi Y, Nakao A, Yoshimura A, et al. Effect of Intratumoral PD-L1 Expression on Treatment Efficacy of ALK Tyrosine Kinase Inhibitors for Advanced or Recurrent ALK-Positive Non-small Cell Lung Cancer. Medical Oncology. 2026. doi:10.1007/s12032-026-03477-2

BibTeX
@article{Sawada2026,
  author = {Sawada, Ryo and Yamada, Tadaaki and Goto, Yasuhiro and Negi, Yoshiki and Nakao, Akira and Yoshimura, Akihiro and Furuya, Naoki and Oba, Tomohiro and Hibino, Makoto and Nakatani, Haruka and Taniguchi, Hirokazu and Ohtsubo, Aya and Watanabe, Satoshi and Yamada, Takahiro and Chihara, Yusuke and Kijima, Takashi and Takayama, Koichi},
  title = {Effect of Intratumoral PD-L1 Expression on Treatment Efficacy of ALK Tyrosine Kinase Inhibitors for Advanced or Recurrent ALK-Positive Non-small Cell Lung Cancer},
  journal = {Medical Oncology},
  year = {2026},
  doi = {10.1007/s12032-026-03477-2}
}
Kostenlos starten →